News

Share

Aa-+

Here is the latest news about the Montreal Heart Institute.
Subscribe to news feed

  • Fighting gut infections contributes to preventing Crohn’s disease and ulcerative colitis.

    November 11, 2021

    A research team from the Montreal Heart Institute (ICM) has shown that genes present in specific intestinal cells protect against the development of inflammatory bowel diseases (IBD). Published today in the scientific journal Genome Medicine, the study results show that more than a dozen of these genes, which contribute to the development of Crohn’s disease and ulcerative colitis, help fight viral and bacterial infections.

    Read more

  • A new world-class hub for clinical research and precision medicine

    October 26, 2021

    Launched as part of the first FACS program call for proposals, and headed by Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, this initiative builds on a network of nearly 100 multidisciplinary experts from industry and academia, as well as a multi-centre network of Quebec hospitals. Its goal is to create a world-class hub for clinical research and precision medicine in the cardiovascular field, and to subsequently broaden its scope to other disciplines such as oncology and neurology.

    Read more

  • Dr. Denis Roy receives the 2021 Canadian Cardiovascular Society Research Achievement Award

    October 21, 2021

    Dr. Denis-Roy, a cardiologist emeritus at the Montreal Heart Institute (MHI), received the Canadian Cardiovascular Society (CCS) Research Achievement Award yesterday at the Canadian Cardiovascular Congress 2021. This prestigious award is given annually to an established investigator working on an aspect of cardiovascular research in Canada.

    Canada’s Interventional Electrophysiology Pioneer

    Read more

  • Dr. Jean-Claude Tardif Receives the Prestigious Margolese National Heart Disorders Prize

    September 10, 2021

    The Montreal Heart Institute (MHI) is proud to announce that Dr. Jean-Claude Tardif has been honoured with the 2021 Margolese National Heart Disorders Prize.

    This prestigious distinction is awarded annually to a Canadian physician or scientist who makes outstanding contributions to heart disorders’ treatment, amelioration, or cure.

    Read more

  • Health Canada approval of low-dose colchicine for cardiovascular disease based on the COLCOT study

    August 27, 2021

    MYINFLA™ 0.5 mg has been approved by Health Canada for the reduction of cardiovascular risk in patients with coronary disease. MONTREAL, August 27, 2021 – People with coronary disease now have a new treatment option to reduce the risk of cardiovascular events. Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.

    Read more

  • Canadian first: The Department of Surgery implants a new biological aortic prosthesis

    June 8, 2021

    The Montreal Heart Institute (MHI) announces that the surgery department has implanted a new biological aortic prosthesis in a patient, a Canadian first. This cutting-edge medical device reduces the time required for surgery and the risk of complications; thus, patients enjoy a better quality of life.

    Read more

  • Results of the COLCORONA study published in The Lancet Respiratory Medicine

    May 27, 2021

    Colchicine could be considered as a treatment for non-hospitalized patients diagnosed with COVID-19 by PCR test and at risk of complications.

    Read more

  • BRAIN-AF Study Receives Canadian Institutes of Health Research Grant

    March 16, 2021


    The Montreal Heart Institute (MHI) announces that the BRAIN-AF study has received a $1.4 million grant from the Canadian Institutes of Health Research. Seeking to better understand the effects of cardiovascular disease on the cognitive decline of the brain, the study will be able to recruit participants remotely thanks to this funding.

    Read more

  • New Clinical Trial on Hesperidin

    February 16, 2021


    A natural product to fight symptoms related to COVID-19

    The Montreal Heart Institute (MHI) is launching a new clinical trial to evaluate the effect of hesperidin on symptoms related to COVID-19. This flavonoid naturally found in citrus fruits has distinct properties that may reduce the entry and replication of the SARS-CoV2 virus in the body along with the modulation of inflammatory mediators, thus potentially reducing symptoms and prevent complications from the disease.

    Read more

  • Caregiver visits suspended at 3rd East and 3rd Center

    January 29, 2021

    Due to an outbreak in the surgical continuum, caregiver visits are suspended indefinitely.

    Caregivers will not be able to come to the surgical intensive care unit (3rd east) and the surgical unit (3rd center) until further notice.

    In exceptional situations or for humanitarian reasons (eg: end of life), a caregiver may be authorized, with the agreement of the care unit.

    Read more

Pages